Pharma BD Deal Intelligence
A mixed-outcome buyout: Daiichi Sankyo paid $805M upfront ($935M total) for Plexxikon and its melanoma drug vemurafenib, but the deal was later rated "Partially Achieved," with financial return the weakest dimension at 50/100.
Daiichi Sankyo / Plexxikon: Partially Achieved (Score: 59/100)
Full analysis, sources & comparables →Daiichi Sankyo nabs tiny Plexxikon in $935M deal to accelerate oncology pipeline and gain proprietary scaffold-based drug discovery platform
Daiichi Sankyo shuttering Plexxikon R&D site in San Francisco as company pivots strategic focus toward antibody-drug conjugate therapies
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Daiichi Sankyo acquired Plexxikon for $805M + $130M milestones for melanoma drug vemurafenib.
Daiichi Sankyo / Plexxikon: Partially Achieved (Score: 59/100)
Assessment window: 15yr post-close.
68K US cases/yr · $2.0B US Melanoma Therapeutics Market (2011) · 56% Reduction in Risk of Death (BRIM3)
~50% of melanoma patients harbor BRAF V600E mutations. Plexxikon discovered vemurafenib (Zelboraf), the first BRAF inhibitor. Daiichi Sankyo acquired Plexxikon for $805M + $130M milestones, gaining co-promotion rights. Zelboraf approved August 2011.
Zelboraf was superseded by BRAF+MEK combinations: dabrafenib+trametinib and vemurafenib+cobimetinib (approved 2015). Checkpoint inhibitors (Opdivo, Keytruda) ultimately became preferred frontline therapy, limiting targeted therapy's commercial ceiling.
Daiichi Sankyo Co. closes acquisition/merger of Plexxikon Inc. for $935M, establishing strategic position and initiating integration.
Strategic Fit: 72/100 | Financial Return: 50/100 | Pipeline Outcome: 58/100 | Integration: 55/100 | Deal Difficulty: 55/100. Partially Achieved overall outcome.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Daiichi Sankyo Company, Limited / Plexxikon Inc. (this deal) | 2011 | $935M | 51 |
| Daiichi Sankyo Company, Limited / Ambit Biosciences | 2006 | $410M | 62 |
| Daiichi Sankyo Company, Limited / Zepharma Inc. | 2006 | $200M | 57 |
| Daiichi Sankyo Company, Limited / Ranbaxy Laboratories Limited | 2008 | $4.6B | 14 |
| Daiichi Sankyo Company, Limited / Nosis Biosciences, Inc. | 2025 | — | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
← Browse all deals · How we score deals
More: 2011 deals · Daiichi Sankyo Company, Limited deals · Oncology deals